Immutep Limited Stock Fundamentals
| PRRUF Stock | USD 0.20 0.00 0.00% |
Immutep Limited fundamentals help investors to digest information that contributes to Immutep's financial success or failures. It also enables traders to predict the movement of Immutep Pink Sheet. The fundamental analysis module provides a way to measure Immutep's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immutep pink sheet.
Immutep |
Immutep Limited Company Return On Equity Analysis
Immutep's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Immutep Return On Equity | -0.38 |
Most of Immutep's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immutep Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Immutep Limited has a Return On Equity of -0.3849. This is 98.39% lower than that of the Healthcare sector and 98.94% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 24.16% higher than that of the company.
Immutep Limited Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immutep's current stock value. Our valuation model uses many indicators to compare Immutep value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immutep competition to find correlations between indicators driving Immutep's intrinsic value. More Info.Immutep Limited is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immutep's earnings, one of the primary drivers of an investment's value.Immutep Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immutep's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Immutep could also be used in its relative valuation, which is a method of valuing Immutep by comparing valuation metrics of similar companies.Immutep is currently under evaluation in return on equity category among its peers.
Immutep Fundamentals
| Return On Equity | -0.38 | |||
| Return On Asset | -0.23 | |||
| Operating Margin | (7.18) % | |||
| Current Valuation | 142.99 M | |||
| Shares Outstanding | 879.09 M | |||
| Shares Owned By Insiders | 4.61 % | |||
| Shares Owned By Institutions | 24.04 % | |||
| Price To Earning | (2.50) X | |||
| Price To Book | 2.81 X | |||
| Price To Sales | 33.12 X | |||
| Revenue | 247.66 K | |||
| Gross Profit | (26.63 M) | |||
| EBITDA | (43.69 M) | |||
| Net Income | (32.21 M) | |||
| Cash And Equivalents | 80 M | |||
| Cash Per Share | 0.09 X | |||
| Total Debt | 2.11 M | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 14.16 X | |||
| Book Value Per Share | 0.11 X | |||
| Cash Flow From Operations | (30.23 M) | |||
| Earnings Per Share | (0.02) X | |||
| Number Of Employees | 17 | |||
| Beta | 1.95 | |||
| Market Capitalization | 171.77 M | |||
| Total Asset | 148.52 M | |||
| Retained Earnings | (222 M) | |||
| Working Capital | 21 M | |||
| Current Asset | 22 M | |||
| Current Liabilities | 1000 K | |||
| Z Score | 47.2 | |||
| Net Asset | 148.52 M |
About Immutep Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immutep Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immutep using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immutep Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia. Immutep operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in Immutep Pink Sheet
Immutep financial ratios help investors to determine whether Immutep Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Immutep with respect to the benefits of owning Immutep security.